First-Line Treatment for Acute Asthma Exacerbation
Albuterol (short-acting beta-agonist) is the first-line treatment for all acute asthma exacerbations, administered via nebulizer (2.5-5 mg every 20 minutes for 3 doses) or metered-dose inhaler with spacer (4-8 puffs every 20 minutes for up to 3 doses), combined with early systemic corticosteroids (prednisone 40-60 mg orally for adults). 1, 2
Initial Assessment and Oxygen Therapy
- Administer supplemental oxygen immediately to maintain oxygen saturation >90% (>95% in pregnant patients or those with heart disease) via nasal cannula or mask 1, 2, 3
- Monitor oxygen saturation continuously until clear response to bronchodilator therapy occurs 1, 2
- Assess severity using symptoms, peak expiratory flow (PEF) or FEV₁, and vital signs to guide treatment intensity 1, 2
Primary Bronchodilator Therapy
Albuterol administration options (both routes are equally effective when properly administered): 1, 3
- Nebulizer route: 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed 1, 2, 4
- MDI with spacer: 4-8 puffs every 20 minutes for up to 3 doses, then as needed 1, 2
- For severe exacerbations (FEV₁ or PEF <40%): Consider continuous nebulization of albuterol rather than intermittent dosing 1, 2
Systemic Corticosteroids - Critical Early Intervention
Administer systemic corticosteroids early in all moderate to severe exacerbations (oral route is as effective as intravenous and less invasive): 1, 2, 3
- Adults: Prednisone 40-60 mg orally in single or divided doses 1, 2, 3
- Children: 1-2 mg/kg/day (maximum 60 mg/day) 1, 2
- Alternative: Dexamethasone 0.6 mg/kg/day (maximum 16 mg/day) for 2 days may be used instead of 5-day prednisone course 2
- Duration: 5-10 days for outpatient "burst" therapy; no tapering necessary for courses <10 days 3
Adjunctive Ipratropium Bromide
Add ipratropium bromide (short-acting muscarinic antagonist) to albuterol for all moderate to severe exacerbations, as this combination reduces hospitalizations, particularly in patients with severe airflow obstruction: 1, 2, 3
- Dosing: 0.5 mg via nebulizer or 8 puffs via MDI every 20 minutes for 3 doses, then as needed 1, 2, 3
- This combination provides greater bronchodilation than albuterol alone 2, 3
Reassessment and Response Monitoring
- Reassess 15-30 minutes after starting treatment by measuring PEF or FEV₁, assessing symptoms, and checking vital signs 1, 2, 3
- Response to treatment is a better predictor of hospitalization need than initial severity 1, 2
- Continue monitoring until patient demonstrates clear clinical improvement 1, 2
Escalation for Severe or Refractory Cases
For severe exacerbations not responding to initial therapy within 1 hour:
- Intravenous magnesium sulfate: 2 g IV over 20 minutes for adults (25-75 mg/kg up to 2 g maximum for children) - most effective when administered early 1, 2, 3
- Consider for patients with FEV₁ or PEF <40% after initial bronchodilator treatment 1, 2
Critical Pitfalls to Avoid
- Never delay systemic corticosteroids - early administration reduces hospitalization rates 1, 2
- Avoid sedatives of any kind in acute asthma exacerbation 1, 2
- Do not use SABA alone without corticosteroids for moderate to severe exacerbations 1, 2
- Monitor for impending respiratory failure: inability to speak, altered mental status, intercostal retractions, worsening fatigue, PaCO₂ ≥42 mmHg 1, 2
- Avoid methylxanthines (theophylline) due to increased side effects without superior efficacy 3
- Regular use of SABA four or more times daily can reduce duration of action 1
Hospital Admission Criteria
Consider hospital admission if: 2
- Life-threatening features present (PEF <33% predicted, silent chest, cyanosis, confusion, altered mental status) 2
- Features of severe attack persist after initial treatment 2
- PEF <50% predicted after 1-2 hours of treatment 3
- History of recent nocturnal symptoms, recent hospital admission, or previous severe attacks 2